Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review

Calcif Tissue Int. 2016 Sep;99(3):322-5. doi: 10.1007/s00223-016-0150-6. Epub 2016 May 18.


Paget's disease is a condition involving focal overactivity of bone cells (osteoblasts and osteoclasts), which can result in significant skeletal morbidity. It is unclear in which bone cells the causative lesion resides. It is managed effectively with potent bisphosphonates, but treatment is difficult if these drugs are contraindicated. We describe a 75-year-old woman with Paget's disease involving the skull who was intolerant of bisphosphonates, so was treated with denosumab. This intervention normalized serum alkaline phosphatase for 4-8 months after each injection and led to some symptomatic improvement. Scintigraphic activity in the lesion was improved but not normalized. We conclude that reduction in RANKL activity by denosumab only partially corrects pagetic activity, indicating that the osteoclast overactivity of Paget's disease is not wholly mediated by RANKL. Denosumab has some clinical utility in Paget's disease and may become a second-line agent in those with contraindications to intravenous bisphosphonates.

Keywords: Alendronate; Denosumab; Paget’s disease.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged
  • Bone and Bones / drug effects
  • Bone and Bones / pathology
  • Denosumab / therapeutic use*
  • Diphosphonates / therapeutic use*
  • Female
  • Humans
  • Osteitis Deformans / diagnosis
  • Osteitis Deformans / drug therapy*
  • Osteitis Deformans / pathology
  • Osteoblasts / drug effects
  • Osteoblasts / pathology
  • Osteoclasts / drug effects*


  • Diphosphonates
  • Denosumab